* Guilford Pharmaceuticals Inc., of Baltimore, said it gainedexclusive worldwide rights to a patent covering delivery of cancerchemotherapeutics in biodegradable polymers for treatment of solidtumors. The patents were licensed from Johns Hopkins University inBaltimore and the Massachusetts Institute of Technology inCambridge, Mass. Financial terms were not disclosed.

* SangStat Medical Corp., of Menlo Park, initiated pivotalbioequivalence trials with its version of cyclosporine, animmunosuppressive drug used to prevent organ transplant rejections.The trials will support the company's FDA application for a genericdrug approval. The product currently is marketed by Sandoz Ltd., ofBasel, Switzerland.

* Synteni Inc., of Palo Alto, Calif., entered a collaboration withHoffmann-La Roche Inc., of Nutley, N.J., to supply thepharmaceutical company with gene expression information. Financialterms were not disclosed. Hoffmann-La Roche, a subsidiary of Basel,Switzerland-based Roche Holding Ltd., will use Synteni's GeneExpression Micro-array technology to analyze expression levels ofthousands of genes.

* The Liposome Co., of Princeton, N.J., said its board adopted ashareholder rights plan to discourage any person or group fromacquiring more than 15 percent of the company's stock. Thecompany said the move was not made in response to any takeoverattempt.

* Vertex Laboratories Inc., of Englewood, Calif., said its controlled-release AZT formulation, Aztec, resulted in significantly reduced sideeffects compared to AZT. Also, only one of 72 Aztec patientsdeveloped resistance compared to 10 of 76 AZT patients.

(c) 1997 American Health Consultants. All rights reserved.